Posted by ABMN Staff on Apr 18th, 2024
Raymond James & Associates cut its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) by 38.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned...
More of this article »